Serial biotech entrepreneur Michael Gilman takes his key to the $100M-plus club and goes all-in on drugging RNA
Scientist and biotech entrepreneur Michael Gilman is joining the $100 million-plus club with his startup Arrakis. And he’s all-in as the developer — one of the more prominent players in a pack of biotechs looking to use small molecules to drug RNA — sets out to transition from platform building to pipeline construction.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,800+ biopharma pros reading Endpoints daily — and it's free.